Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Discovery Grants Program - Individual

University of Ottawa

$35,000.00

Aptamer-facilitated technologies for cell activity modulation and imaging

EF 2014-15

Résumé
One of the most challenging tasks of bioanalytical chemistry and biotechnology is the replacement of animal- or hybridoma-made antibodies with artificial competitors that can be easily selected and chemically synthesized. Such competitors are aptamers - single-stranded DNA or RNA oligonucleotides that can bind to a variety of different targets ranging from small molecules to proteins with high affinity and specificity. Aptamers are ligands with big potential to change the field of affinity probes and to replace antibodies as diagnostic and therapeutic reagents. In contrast to antibodies, they do not trigger an immune response. They are thermostable and can be chemically synthesized for lower price, have better batch-to-batch reproducibility, and have the simplicity of chemical modifications and integration in biosensors.In the grant, I propose several important aptamer-based developments which cannot be achieved with antibodies: 1) the selection of ""smart"" aptamers with desirable binding parameters to cell surface proteins, 2) technology development for whole cell recognition and detection of microbial pathogens, 3) the development of cell specific aptamers for high-contrast cellular imaging and treatment of metastatic cancer. At present time, there are no methods available for generating antibodies directed to a specific protein in the presence of other antigens. Only aptamers can be selected in vitro procedure for the protein in extremely complex mixtures: inside a cell or on a cell membrane surrounded by other biomolecules. The important feature of my proposed technologies is that they produce aptamers simultaneously with biomarker discovery. I will develop aptamers for bacterial and cancer cell surface biomarkers in their native state and conformation. Such aptamers will be directly utilized for pathogen detection, cell isolation, visualization of metastases, and for tracking of tumor cells in vivo. Finally, they could be used to modulate activities of cell receptors or to deliver different agents (conjugated peptide toxins, siRNA, and small molecule drugs) to the cells with the aim of treating cancer.
Programme
Discovery Grants Program - Individual
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
385739-2010
Name nom
Berezovski, Maxim
Department département
Chemistry
Organization id
28
Institution établissement
University of Ottawa
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2014
Competition year année de concours
2010
Award amount
35000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
1504
Committee name en
Chemistry
Committee name fr
Chimie
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
3504
Research subject group en
Analytical chemistry
Research subject group fr
Chimie analytique
Research subject en
Bioanalytical chemistry
Research subject fr
Chimie bioanalytique
Partie
5
Nb partie
5
Application title
Aptamer-facilitated technologies for cell activity modulation and imaging
Keyword
NSERC
Application summary
One of the most challenging tasks of bioanalytical chemistry and biotechnology is the replacement of animal- or hybridoma-made antibodies with artificial competitors that can be easily selected and chemically synthesized. Such competitors are aptamers - single-stranded DNA or RNA oligonucleotides that can bind to a variety of different targets ranging from small molecules to proteins with high affinity and specificity. Aptamers are ligands with big potential to change the field of affinity probes and to replace antibodies as diagnostic and therapeutic reagents. In contrast to antibodies, they do not trigger an immune response. They are thermostable and can be chemically synthesized for lower price, have better batch-to-batch reproducibility, and have the simplicity of chemical modifications and integration in biosensors.In the grant, I propose several important aptamer-based developments which cannot be achieved with antibodies: 1) the selection of ""smart"" aptamers with desirable binding parameters to cell surface proteins, 2) technology development for whole cell recognition and detection of microbial pathogens, 3) the development of cell specific aptamers for high-contrast cellular imaging and treatment of metastatic cancer. At present time, there are no methods available for generating antibodies directed to a specific protein in the presence of other antigens. Only aptamers can be selected in vitro procedure for the protein in extremely complex mixtures: inside a cell or on a cell membrane surrounded by other biomolecules. The important feature of my proposed technologies is that they produce aptamers simultaneously with biomarker discovery. I will develop aptamers for bacterial and cancer cell surface biomarkers in their native state and conformation. Such aptamers will be directly utilized for pathogen detection, cell isolation, visualization of metastases, and for tracking of tumor cells in vivo. Finally, they could be used to modulate activities of cell receptors or to deliver different agents (conjugated peptide toxins, siRNA, and small molecule drugs) to the cells with the aim of treating cancer.